Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merit Medical (MMSI) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.64 per share a year ago.

Merit Medical (MMSI) Beats Q1 Earnings and Revenue Estimates

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for First Quarter Ended March 31, 2024

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Merit Medical (MMSI) is a Strong Value Stock

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024.

Merit Medical Systems to Announce First Quarter 2024 Results on April 30, 2024

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Merit Medical (MMSI) is a Top Value Stock for the Long-Term

Merit Medical to host SIR attendees at Salt Lake City headquarters and SIR booth 320 Merit Medical to host SIR attendees at Salt Lake City headquarters and SIR booth 320

Merit Medical to Host Evening of Innovation during the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

Merit Medical Systems, Inc. (MMSI) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics

Merit Medical (MMSI) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.79 per share a year ago.

Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates

*  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 - Issues Fiscal Year 2024 Guidance

SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026.

Merit Medical Introduces “Continued Growth Initiatives” Program and Financial Targets for Three-Year Period Ending December 31, 2026

Besides Wall Street's top -and-bottom-line estimates for Merit Medical (MMSI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Stay Ahead of the Game With Merit Medical (MMSI) Q4 Earnings: Wall Street's Insights on Key Metrics

Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.

Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

Align Technology

Investors interested in Medical - Dental Supplies stocks are likely familiar with Merit Medical (MMSI) and Align Technology (ALGN). But which of these two stocks presents investors with the better value opportunity right now?

MMSI vs. ALGN: Which Stock Is the Better Value Option?

Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Merit Medical (MMSI) Could Beat Earnings Estimates Again

Merit Medical Systems, Inc. (MMSI) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MMSI's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Should You Buy Merit Medical (MMSI) After Golden Cross?

Reasons to Add Merit Medical (MMSI) to Your Portfolio Now

SOUTH JORDAN, Utah, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis (MOTION) study.

News for Merit Medical Systems Stock (MMSI)